HAVN Life Sciences Inc. Stock

Equities

HAVN

CA4196213058

Biotechnology & Medical Research

Market Closed - Canadian Securities Exchange 02:12:37 2023-11-09 pm EST 5-day change 1st Jan Change
0.03 CAD -.--% Intraday chart for HAVN Life Sciences Inc. +20.00% -.--%
Sales 2021 - Sales 2022 0.28 0.38 Capitalization 10.7M 14.64M
Net income 2021 -30M -41.07M Net income 2022 -22M -30.12M EV / Sales 2021 -
Net cash position 2021 8.95M 12.25M Net cash position 2022 666K 912K EV / Sales 2022 36,279,535 x
P/E ratio 2021
-1.38 x
P/E ratio 2022
-0.4 x
Employees -
Yield 2021 *
-
Yield 2022
-
Free-Float 96.5%
More Fundamentals * Assessed data
Dynamic Chart
1 year
0.00
Extreme 0
0.05
3 years
0.00
Extreme 0
24.00
5 years
0.00
Extreme 0
45.60
10 years
0.00
Extreme 0
45.60
More quotes
Managers TitleAgeSince
Chief Executive Officer 66 20-05-05
Chief Operating Officer - 21-02-28
Director/Board Member - 20-09-03
Members of the board TitleAgeSince
Chief Executive Officer 66 20-05-05
Director/Board Member - -
Director/Board Member - 20-09-03
More insiders
HAVN Life Sciences Inc. is a Canada-based biotechnology company. The Company is engaged in the scientific research and development of psychopharmacological and natural health care products. It is focused on standardizing extraction of psychoactive compounds, the development of natural health products, and developing mental health treatments to support brain health and enhance the capabilities of the mind. The Company has two business divisions: HAVN Labs and HAVN Retail. The HAVN Labs division is engaged in the development of research protocols to cover the production of Psilocybe spp. Through its research division, HAVN Labs, it has developed an end-to-end supply chain of GMP naturally derived psychedelic compounds for research. The HAVN Retail division formulates and sells natural health products (NHPs) using compounds. It offers a full range of mushroom and plant extracts that help boost immune function, reduce inflammation and support a healthy lifestyle.
More about the company